

Primary Lymphoma of the Central Nervous System: Manitoba Experience and Literature Review

Douglas E. Hobson, Brian A. Anderson, Ian Carr and Michael West

ABSTRACT: We describe eight cases of primary cerebral lymphoma seen in Manitoba from 1980 to 1985.

The clinical presentation is similar to other primary brain tumors. The diagnosis should be considered when single or multiple, often deep lesions, show dense enhancement on computerized tomographic (CT) scan, but are avascular at angiography. These tumors are histologically indistinguishable from non-Hodgkins lymphomas arising outside the CNS.

The prognosis is poor. However, radiotherapy with or without surgery may offer significant palliation. Although there is no consensus on the value of chemotherapy, corticosteroids alone or multiagent chemotherapy have shown promise in a few cases. For these reasons, histologic diagnosis should be sought in all cases and surgery, radiotherapy, and chemotherapy should be considered, as prolonged survival is possible.

RÉSUMÉ: Les lymphomes primaires du système nerveux central: Expérience au Manitoba et revue de la littérature
Nous décrivons 8 cas de lymphome cérébral primaire vus au Manitoba de 1980 à 1985. La présentation clinique est semblable à celle des autres tumeurs primaires du cerveau. Le diagnostic doit être considéré lorsque des lésions, souvent profondes, simples ou multiples, montrent une densité augmentée à la tomographie, tout en étant avasculaires à l'angiographie. Ces tumeurs ne peuvent être distinguées des lymphomes non-Hodgkin originant en dehors du S.N.C.

Le pronostic est mauvais. La radiothérapie, avec ou sans chirurgie, peut offrir un soulagement valable. Même s'il n'existe pas de consensus sur la valeur de la chimiothérapie, quelques cas semblent avoir été aidés par les corticostéroïdes seuls ou la chimiothérapie à agents multiples. A cause de ces résultats, une confirmation histologique s'impose et l'on devrait envisager la chirurgie, la radiothérapie et la chimiothérapie, car certaines longues survies sont possibles.

Can. J. Neurol. Sci. 1986; 13:55-61

Primary lymphoma of the CNS constitutes 0.85 to 1.5% of primary brain tumors.^{1,2} They are diagnosed more often than before, partly due to improved diagnostic procedures. Some suspect an increase in incidence related to the increased use of radiotherapy and immunosuppressants.²

Association with renal transplantation,³ adult immunodeficiency syndrome,⁴ systemic lupus erythematosus,⁵ Sjogren's syndrome,⁶ rheumatoid arthritis,⁷ and immunoglobulin A deficiency⁸ has been reported. This suggests a relationship to chronic antigenic stimulation.⁹ Louie¹⁰ suggested the tendency for occurrence in immunosuppressed hosts may indicate a failure of B lymphocyte regulation by T lymphocytes resulting in neoplastic proliferation of these cells. Most primary CNS lymphomas,

however, arise sporadically in patients who have not received immunosuppression and they recapitulate the spectrum of lymphomas arising outside of the CNS.¹¹

These tumors were once known by a variety of names — notably microglioma and reticulum cell sarcoma. More recently ultrastructural and immunologic studies have shown that they are derived from B lymphocytes,^{12,13} and therefore, should be classified like other malignant lymphomas.

The purpose of this report is to describe eight cases of CNS lymphoma seen in Manitoba and to review the literature. Clinical presentation, radiologic, and histologic features and treatment are discussed.

From the Departments of Medicine (Drs. Hobson and Anderson), Pathology (Dr. Carr), and Surgery (Dr. West), University of Manitoba, Winnipeg
Received May 14, 1985. Accepted in revised form September 24, 1985

Reprint requests to: Dr. Brian A. Anderson, Department of Medicine, St. Boniface Hospital, 409 Tache Avenue, Winnipeg, Manitoba, Canada R2H 2A6

MATERIAL AND METHODS

Review of hospital records revealed eight cases of primary lymphoma of the CNS presenting to Manitoba's two teaching hospitals (referral population 1,200,000) between January 1980 and December 1984. The charts of these cases were reviewed. Approximately 550 other primary brain tumors presented during this time span.

RESULTS AND DISCUSSION

Our eight cases are described in Table 1. The staging process included hematologic workup (including bone marrow aspiration and biopsy), SMA-12, chest x-ray, and radionuclide liver and spleen scan. In addition, cases 4, 5, 7, and 8 had normal abdominal CT scans. Cases 1 and 6 had negative lymphangiograms; cases 3 and 4 had normal intravenous pyelograms. All eight cases were diagnosed pre-mortem by surgical procedures outlined in Table 1. Five cases are still alive. In two of the deaths, autopsy confirmed Stage I disease. No autopsy was

performed in the other death. Data from our cases are combined with the series reported in the literature and presented in Table 2. CSF findings are included in Table 4.

Clinical Presentation

These tumors occur from infancy to old age with a peak occurring in the first decade and from the fourth to the seventh decade.¹⁴ The average age in 352 cases reviewed was 52. Male to female ratio was 1.9:1.0.

The most common presenting symptoms and signs were nonspecific and nonlocalizing (>80%). They included headache, nausea and vomiting, possibly implicating raised intracranial pressure (56%). Confusion, memory loss, and personality change also occurred (32%). Focal neurologic symptoms and signs were seen in 42%. Seizures occurred in 9%.

The average duration of symptoms prior to diagnosis was 2.8 months. Our Case 3 is of interest as it suggests the possibility of a primary cerebral lymphoma presenting with seizures 12 years prior to diagnosis, the longest duration reported in the literature.

Table 1: Clinical features, radiologic findings, treatment and outcome in 8 cases of primary CNS lymphoma

| Case | Age/ Sex | Clinical Presentation (Duration of Symptoms Prior to Diagnosis) | Radiologic Characteristics | Surgical Treatment | Histologic Classification (Rappaport) | Radiotherapy and/or Chemotherapy | Follow-Up |
|------|-------------|--|--|------------------------------------|---|--|--|
| 1. | 75 F | Headache, confusion, periodic vertigo, ataxia: on exam, dysarthric speech L arm & leg cerebellar signs (1 month) | CT scan: L cerebellar enhancing mass adjacent to petrous bone; hydrocephalus. Angiography: avascular mass | Complete excision | Histiocytic | none | Died of sepsis, 1 mo. Post-mortem showed no residual CNS lymphoma and no lymphoma outside CNS |
| 2. | 70 F | Headache, dizziness; on exam, ?mild expressive dysphasia (1.5 months) | CT scan: enhancing mass, L frontal lobe adjacent to lateral ventricle. Angiography: not done | Partial excision | Histiocytic | Whole brain radiation: 3500 rads; intrathecal methotrexate | Asymptomatic and CT scan normal at 18 months. |
| 3. | 66 M | R focal motor seizures x 12 years; Expressive aphasia, R hemiparesis, drowsy (0.5 months) | CT scan: enhancing mass, L temporal lobe. Angiography: avascular mass. | Partial excision | Histiocytic | Whole neuro-axis radiation: 4500 rads | Good recovery at 6 months. |
| 4. | 57 M | R arm paresthesias, R hemiparesis, confusion (0.5 months) | CT scan: enhancing lesions in L frontal & parietal lobes and in splenium of corpus callosum | Needle Biopsy | Histiocytic | Whole brain radiation: 5000 rads; dexamethasone | Died 38 months later. Tumor regressed with dexamethasone but recurred (see discussion under treatment) |
| 5. | 78 M | Confusion, L hemiparesis (sudden onset) | CT scan: enhancing mass, L frontal lobe. Angiography: avascular mass | Total excision | Poorly differentiated lymphocytic | Whole brain radiation: 5000 rads; dexamethasone | Mild left arm weakness at 3 months |
| 6. | 70 M | Confusion, aphasia, R hemiparesis (2 months) | CT scan: enhancing frontal mass (butterfly distribution). Angiography: vascular mass | Biospy | Well differentiated lymphocytic | Whole brain radiation 5000 rads; CMOPP chemotherapy regime | Well at 24 months; mild aphasia. |
| 7. | 73 F | Lethargy, L hemiparesis, ataxia (1.5 months) | CT scan: enhancing lesion in R temporal lobe adjacent to skull; thinning of adjacent skull bone seen. Angiography: not done. | Complete excision of temporal mass | Histiocytic | Whole brain radiation: 3000 rads; dexamethasone | Died 2 months post-operatively of sepsis; no residual tumor was discovered at autopsy. |
| 8. | 79 F | Recurrent episodes of confusion with ?aphasia for 2 months; admitted with persistent receptive aphasia & early papilledema | CT scan: enhancing lesion, medial L temporal lobe. Angiography: avascular mass | Partial excision | Histiocytic | Whole brain radiation: 5000 rads | Well at 9 months; minor residual aphasia. |

Table 2: Summary of primary cerebral lymphoma series reported in the literature (present study included)

| | Number of cases | | | Location | | | | | Presenting symptoms | | | | Duration of symptoms prior to diagnosis (months) | Classification (Rappaport system) | | | | | |
|--------------------------|-----------------|---------|----------|----------|------------|---------------------|-------------|----------|-------------------------|-------------------|---------------|---------|--|-----------------------------------|--------------------------|-------|-------------|---------------|------------------|
| | M | F | Ave. age | Cerebrum | Cerebellum | Deep structures (C) | Spinal cord | Multiple | ↑Cranial pressure & (D) | Memory loss & (E) | Focal deficit | Seizure | | Lymphocytic well diff. | Lymphocytic poorly diff. | Mixed | Histiocytic | Lymphoblastic | Undifferentiated |
| Kinney ⁴⁶ | 7 | 7-0 | 44 | 7 | 0 | 0 | 0 | 0 | 7 | 4 | 0 | 0 | 6 | — (A) — | | | | | |
| Burnstein ¹⁴ | 41 | 22-19 | 44 | 24 | 8 | 2 | 0 | 7 | 29 | (A) | 6 | 0 | 3 | — (A) — | | | | | |
| Schaumberg ¹⁶ | 25 | 13-12 | 66 | 17 | 3 | 1 | 0 | 3 | 12 | 6 | 13 | 0 | 2.5 | — (A) — | | | | | |
| Henry ²⁹ | 83 | 62-21 | 52 | 70 | 14 | 21 | 4 | 22 | 29 | 28 | 35 | 8 | 2.5 | -19- | 0 | 40 | 9 | 0 | |
| Jellinger ¹ | 68 | 40-28 | 55 | 34 | 7 | 12 | 0 | 15 | (A) | (A) | (A) | (A) | 3.3 | 10 | 39 | 0 | 11 | 0 | 0 |
| Littman ³⁰ | 19 | 10-90 | 56 | 14 | 4 | 1 | 0 | 0 | 10 | 7 | 6 | 1 | 2.8 | — (A) — | | | | | |
| Tanaka ⁴⁷ | 6 | 4-2 | 51 | 5 | 0 | 1 | 0 | 0 | 3 | 1 | 4 | 1 | (A) | — (A) — | | | | | |
| Taylor ¹³ | 24 | 18-6 | 55 | (A) | (A) | (A) | (A) | (A) | (A) | (A) | (A) | (A) | (A) | 0 | 8 | 1 | 14 | 0 | 1 |
| Spillane ²¹ | 20 | 13-7 | 51 | 14 | 1 | 16 | 0 | 6 | 28 | 13 | 16 | 6 | 2.0 | — (A) — | | | | | |
| Letendre ⁴⁸ | 17 | 12-5 | 57 | 15 | 1 | 2 | 0 | 1 | 12 | 2 | 15 | 0 | (B) | 0 | 7 | 1 | 9 | 0 | |
| Mendenhall ⁹ | 12 | 9-3 | 51 | 8 | 2 | 3 | 0 | 1 | 4 | 8 | 9 | 2 | 3 | — (A) — | | | | | |
| Helle ¹¹ | 22 | 16-6 | 44 | 15 | 6 | 10 | 1 | 10 | 8 | 5 | 12 | 3 | 2 | 0 | 1 | 2 | 11 | 0 | 6 |
| Present study | 8 | 4-4 | 71 | 5 | 1 | 1 | 0 | 2 | 5 | 8 | 5 | 1 | 1.6 | 1 | 1 | 0 | 6 | 0 | 0 |
| Totals | 352 | | | 228 | 47 | 70 | 5 | 67 | 147 | 82 | 121 | 23 | | — (A) — | | | | | |
| Average | | 1.9-1.0 | 52 | | | | | | | | | | 3 months | | | | | | |
| Percent | | | | 55 | 11 | 17 | 1 | 16 | 56 | 32 | 42 | 9 | | 43 | 43 | 2 | 46 | 56 | 4 |

(A) -Precise information not given in study

(B) -Range 1 to 84 months

(C) -Refers to basal ganglia, thalamus and/or other periventricular locations

(D) -Includes nonspecific signs, headache, nausea, vomiting

(E) -Personality change, confusion

Location

Fifty-five percent of tumors occurred in the cerebral white matter, often within or close to the corpus callosum. Some had a butterfly appearance as seen with some glial tumors. Seventeen percent occurred in deep structures (basal ganglia, thalamus, hypothalamus, periventricular white matter). Eleven percent were in the posterior fossa. One percent involved the spinal cord. They were distinctly uncommon superficially, but have rarely been reported to be localised to the leptomeninges.¹⁵ Multiple tumors occurred in 16% of cases.

Radiologic Characteristics

This topic has been reviewed by many authors.^{9,16-22} Skull films²³ and radionucleotide brain scans¹⁸ were abnormal in many cases but did not provide information to help identify the tumor type.

The CT scan characteristics of 29 primary cerebral lymphomas have been described²¹ using CT scanning without contrast infusion. Twenty-one tumors were dense, five were isodense, two hypodense, and one had variable density in relation to surrounding normal brain tissue. Following contrast infusion, the majority (70%) showed dense homogeneous enhancement. Ten percent showed no enhancement and 20% irregular enhancement. Tallroth¹⁹ also described dense enhancement in the majority of his cases.

Thomas²² separated his cases into two groups on the basis of the CT scan characteristics. Deep lesions tended to be well demarcated with little mass effect or surrounding edema, and

showed marked homogeneous enhancement. More superficial lesions tended to be poorly demarcated. They had variable density with significant surrounding edema and tended to enhance irregularly. Our results supported this observation.

Ninety-one percent of angiograms performed were abnormal (Table 3). Sixty-three percent showed a mass lesion without increased vascularity. Tumor blush was seen in 28%.

Neither the angiographic nor CT scan appearance is diagnostic of primary cerebral lymphoma. The radiologic picture may suggest glioma, meningioma, or metastatic carcinoma. However, a densely enhancing lesion on CT scan which is avascular on an angiogram should raise suspicion. Multiple lesions with similar characteristics, especially if deeply situated, should also suggest primary cerebral lymphoma¹⁹.

Cerebrospinal Fluid (CSF) Abnormalities

Eighty-one percent of reported spinal fluid examinations were abnormal with increased protein in 100% of those (Table 4). An increased cell count, most frequently mononuclear, was seen in 42%. The accuracy of CSF cytologic diagnosis ranges from 4% to 43.5%.²⁴ Jellinger²⁴ suggests that immunologic studies on CSF might be of value. Analysis of CSF protein may show increased levels of immunoglobulins. More studies are needed to determine if such abnormalities would assist in making tumor-specific diagnosis. Unfortunately, as seen in Table 4, only two of our cases had lumbar punctures. Both were abnormal with positive cytology in one. Immunologic studies were not done.

Table 3: Angiographic findings in 68 cases of primary cerebral lymphoma

| Study | Number | RESULTS | | |
|--------------------------|--------|---------|----------------|--------------|
| | | Normal | Avascular Mass | Tumour Blush |
| Helle ¹¹ | 13 | 0 | 8 | 5 |
| Spillane ²¹ | 10 | 0 | 7 | 3 |
| Letendre ⁴⁸ | 15 | 1 | 7 | 7 |
| Schaumberg ¹⁶ | 18 | 3 | 13 | 2 |
| Enzmann ¹⁸ | 7 | 0 | 6 | 1 |
| Present Study | 5 | 1 | 2 | 2 |
| Total | 68 | 5 | 43 | 20 |
| Percentage of Total | | 9% | 63% | 28% |

Table 4: Cerebrospinal fluid findings in 124 cases of primary cerebral lymphoma

| Study | Number of Cases | Number Abnormal | Increased Cell Count | Increased Protein | Cytology |
|--------------------------|-----------------|-----------------|----------------------|-------------------|----------------------|
| Helle ¹¹ | 9 | 7 | 4 | 7 | negative |
| Littman ³⁰ | 11 | 9 | 5 | 9 | negative |
| Henry ²⁹ | 45 | 35 | 14 | 35 | not done |
| Schaumberg ¹⁶ | 17 | 14 | 5 | 13 | positive in 1 of 2 |
| Jellinger ¹ | 40 | 34 | 23 | 34 | positive in 27 of 40 |
| Present Study | 2 | 2 | 1 | 2 | positive in 1 of 2 |
| Total | 124 | 101 | 52 | 100 | variable |
| Percentage of Total | | 81% | 42% | 81% | |




Figure 1 — Serial CT scans in Case 4. — a) Initial CT scan, two weeks post-onset of symptoms. Enhancing lesions left frontal and parietal lobes and splenium of corpus callosum. — b) Repeat scan six months later showing marked resolution of the lesions after dexamethasone treatment. Non-enhancing low density areas are seen in the left frontal white matter and left globus pallidus (arrows). Patient was asymptomatic at this time. — c) After a further eight months the patient was again symptomatic. Scans show recurrence of enhancing tumor.

Pathologic Characteristics

At the time of surgery these tumors are most often found to be soft greyish-pink masses¹⁶ which can extend to involve meningeal and ependymal surfaces. In two of our cases, the texture was firm, rubbery and lobulated, resembling a meningioma.

Our cases were classified using the Rappaport Classification.²⁵ The majority of reported cases are lymphocytic or histiocytic (Table 2). Six of our eight cases were histiocytic, one was a poorly differentiated lymphocytic, and the other a well differentiated lymphocytic lymphoma (Table 2). It is now generally accepted that the great majority of these neoplasms are B-cell derived. Cytologic and immunologic analyses allows identification of B-cell subtypes predominant within a tumor.²⁶ There is, to date, no good evidence that this subclassification is of prognostic significance. As well, this information is not currently used in selecting treatment. The use of monoclonal antibodies on paraffin-embedded tissue can help distinguish lymphomas from other small cell tumors. This latter method does not help differentiate from other inflammatory disorders, but is particularly helpful if biopsy material is limited.²⁷

PROGNOSIS AND TREATMENT

The overall prognosis of primary malignant CNS lymphoma is worse than extranodal lymphoma occurring elsewhere.²⁸ Helle¹¹ concluded that a primary CNS lymphoma of diffuse mixed histology or one arising infratentorially is associated with a worse prognosis.

It is generally agreed^{1,14,29} that cranial radiation significantly improves survival. The survival statistics of 68 patients were discussed in the review by Jellinger¹ and the results were representative of those found elsewhere. The mean survival was two months in those receiving no therapy, one month in those receiving surgery alone, and 16 months in patients treated with surgery and cranial radiation. Mean survival for as long as 45 months has been reported in the latter treatment group.¹⁴

Surgery is suggested if a well localised lesion can be safely removed.³⁰ Overzealous surgery may increase the deficit without improving the long term course. Radiotherapy is an essential complement to any surgical therapy.

The exact dose and field of radiation is debated. Sagerman²³ reported a high percentage of recurrence with total doses below 3500 rads. Littman³⁰ concluded that a total dose between 4500 and 5500 rads was the treatment of choice. More recently Mendenhall⁹ has recommended 4000 to 4500 rads of whole brain radiation with an additional 1500 to 2000 rads to a reduced field around the primary. There is concern however that this "boost" to the tumor may increase the risk of radiation induced encephalopathy.³¹

Littman³⁰ suggested spinal axis radiation be given in those cases with positive CSF cytology. Rampen³¹ and Mendenhall⁹ recommended spinal axis radiation in all cases, the recommended dosage being 3000 to 3500 rads.

All patients should have ophthalmologic examination to rule out lymphomatous vitreous involvement.⁹ This association is not uncommon and nongranulomatous uveitis has been reported as a presenting feature by several authors.^{32,33,34} If positive, orbital radiation should be given.

No large study of chemotherapy for these tumors has been done. Drugs effective for non-CNS lymphoma (bleomycin, cyclophosphamide, adriamycin, vincristine) have poor blood-brain-barrier penetration.⁹ Radiosensitizers should be of benefit but tend to have little effect on lymphomas.⁹

Several case reports have suggested some benefit from multiple drug therapy.^{9,30,35} Our case 6 remains alive two years post-treatment with the cyclophosphamide, methotrexate, vincristine, prednisone regime. Amadori³⁶ described eight patients with active CNS leukemia and lymphoma whom he treated with a combination of high dose cytosine arabinoside and asparaginase. The former drug has good CNS penetration and the latter is synergistic with it. He suggested the therapy was well tolerated and highly effective in terms of CNS tumor regression. Although none of his cases were primary to the CNS, this therapy might be considered for primary cerebral lymphoma.

Intrathecal methotrexate has been used with some success.³⁷ However, there is a risk of necrotizing leukoencephalopathy when this drug is combined with cranial radiation.³⁸

Dexamethasone as a chemotherapeutic agent for CNS lymphoma has received little attention. We have noted dramatic improvement in our case 4 (Table 2). This 57 year old male presented with mild right hemiparesis. CT scan showed enhancing lesions in the left frontal and parietal lobes, and in the splenium of the corpus callosum (Figure 1a). Clinical symptoms and signs resolved in two weeks with dexamethasone, 16 milligrams orally per day. Serial CT scans showed marked resolution of the lesions (Figure 1b). Dexamethasone was then tapered and stopped over the next six months. No other treatment was given and the patient was asymptomatic for the next year. Symptoms then recurred at which time a repeat CT scan showed recurrent tumor (Figure 1c). Needle biopsy showed histiocytic lymphoma. Five thousand rads of whole brain radiation and dexamethasone provided partial palliation but death occurred eight months later. Cases with a similar marked response to corticosteroids have been described in the literature.⁴⁰⁻⁴⁵

CONCLUSION

Primary lymphoma of the CNS remains an uncommon disease. The keys to diagnosis are a high index of suspicion and pathologic confirmation. Treatment modalities beyond radiotherapy require controlled studies before a specific regime can be universally recommended.

ACKNOWLEDGEMENTS

We would like to thank Dr. R. T. Ross, Dr. N. Pillay, and Dr. A. Gomori for their suggestions, and Gail Landry for assistance with manuscript preparation.

REFERENCES

1. Jellinger K, Radaskiewicz T, Slowik F. Primary malignant lymphomas of the central nervous system in man. *Acta Neuropath (Berlin)* 1975; Supp VI, 95-102.
2. Zimmerman H. Malignant lymphomas of the nervous system. *Acta Neuropath (Berlin)* 1975; Supp VI, 69-74.
3. Schneck S, Penn I. Cerebral neoplasms associated with renal transplantation. *Arch Neurol* 1970; 22: 226-233.
4. Scully R, Mark E, McNeely B. Case records of the Massachusetts General Hospital, Case 32, 1983. *New Eng J Med* 1983; 309: 359-369.
5. Lipsmeyer EA. Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression. *Arthritis Rheum* 1972; 15: 183-186.
6. Klassen SS, Hoover R, Kimberly R, Budman OR, Decker JL, Chused TM. Increased incidence of malignancy in Sjogren's syndrome (SS)(Abstr) *Arthritis Rheum* 1977; 20: 123.
7. Good EA, Russo RH, Schnitzer B, Weatherbee L. Intracranial histiocytic lymphoma with rheumatoid arthritis. *J Rheumatology* 1978; 5: 75-78.
8. Gregory MC, Hughes JT. Intracranial reticulum cell sarcoma associated with immunoglobulin A deficiency. *J Neurol Neurosurg Psychiat* 1973; 36: 769-776.
9. Mendenhall NP, Thar TL, Agee OF, Harty-Golder B, Ballinger WE, Million RR. Primary lymphoma of the CNS. Computerized tomography scan characteristics and treatment results for 12 cases. *Cancer* 1983; 52: 1993-2000.
10. Louie S, Schwartz RS. Immunodeficiency and the pathogenesis of lymphoma and leukemia. *Semin Hematology* 1978; 15: 117-138.
11. Helle T, Britt R, Colby T. Primary lymphoma of the central nervous system — clinicopathologic study of experience of Stanford. *J Neurosurgery* 1984; 60: 94-103.
12. Horvat B, Pena C, Fisher E. Primary reticulum cell sarcoma (microglioma) of brain — an electron microscopic study. *Arch Path* 1969; Vol 87: 609-616.
13. Taylor C, Russell R, Lukes R, David R. An immunohistological study of immunoglobulin content of primary central nervous system lymphomas. *Cancer* 1978; 41: 2197-2205.
14. Burnstein S, Kernohan J, Uihlein A. Neoplasms of the reticuloendothelial system of the brain. *Cancer* 1963; 16: 290-305.
15. March WL Jr, Stevenson DR, Long HJ. Primary leptomeningeal presentation of T-cell lymphoma. Report of a patient and review of the literature. *Cancer* 1983; 51: 1125-1131.
16. Schaumberg H, Plank C, Adams R. The reticulum cell sarcoma-microglioma group of brain tumors. *Brain* 1972; 95: 199-212.
17. Kazner E, Wilske J, Steinhoff H et al. Computed assisted tomography in primary malignant lymphomas of the brain. *J Comp Assist Tomography* 1978; 2: 125-134.
18. Enzmann D, Krikorian J, Norman D, Kramer R, Pollock H, Faer M. Computed tomography in primary reticulum cell sarcoma of the brain. *Radiology* 1979; 130: 165-170.
19. Tallroth K, Kateue K, Holst L, Andersson U. Angiography and computed tomography in the diagnosis of primary lymphoma of the brain. *Clinical Radiology* 1981; 32: 383-388.
20. Thomson J, Brownell B. Computer tomographic appearances in microgliomatosis. *Clinical Radiology* 1981; 32: 367-374.
21. Spillane J, Kendal B, Moseley I. Cerebral lymphoma: clinical radiological correlation. *J Neurol Neurosurg Psychiat* 1982; 45: 199-208.
22. Thomas M, MacPherson P. Computed tomography of intracranial lymphoma. *Clinical Radiology* 1982; 33: 331-336.
23. Sagerman RH, Cassaday JR, Chang CH. Radiation therapy for intracranial lymphoma. *Radiology* 1967; 88: 552-554.
24. Jellinger K. Primary lymphomas of the CNS. *Arch Neurology* 1982; 39: 458.
25. Rappaport H. Tumors of the hematopoietic system. In: "Atlas of tumor pathology", 1966; Washington DC, Armed Forces Institute of Pathology, Section III, Fascicle 8, p. 99-101.
26. Robbins SL, Cotran RS, Kumar V. Pathologic bases of disease, 1984; Chapter 15, Diseases of white cells, lymph nodes and spleen, 3rd edition, W.B.Saunders, p. 653-704.
27. Warnke RA, Gatter KC, Brunangelo F, Hildreth P, Woolston RE, Pulford K, Cordell JL, Cohen B, De Wolf-Peters C, Mason DY. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. *New Eng J Med* 1983; 309: 1275-1281.
28. Mukherji B, Yagoda A, Lee BH, Kraddock IH. A clinical study of the natural history of lymphosarcoma and reticulum cell sarcoma. *Eur J Cancer* 1974; 10: 497-505.
29. Henry J, Heffner R, Dillard S, Earle K, Davis R. Primary malignant lymphoma of the central nervous system. *Cancer* 1974; 34: 1293-1302.
30. Littman P, Wang CC. Reticulum cell sarcoma of the brain: A review of the literature and a study of 19 cases. *Cancer* 1975; 35: 1412-1420.
31. Rampen FH, Van An del JG, Sizoo W, Unnik J. Radiation therapy in primary non Hodgkin's lymphoma of the CNS. *Eur J Cancer* 1980; 16: 177-184.
32. Givner I. Malignant lymphoma with ocular involvement. A clinicopathologic report. *Am J Ophthalmol* 1955; 39: 29-32.
33. Parver LM, Font RL. Malignant lymphoma of the retina and brain. Initial diagnosis by cytologic examination of vitreous aspirate. *Arch Ophthalmol* 1979; 97: 1505-1507.
34. Rosenbaum TJ, MacCarty, CS, Buettner H. Uveitis and cerebral reticulum-cell sarcoma (large-cell lymphoma). Case Report. *J Neurosurg* 1979; 50: 660-664.
35. Stewart DJ, Russell N, Atack EA, Quarrinton A, Stolback L. Cyclophosphamide, doxorubicin, vincristine and dexamethasone in primary lymphoma of the brain: A Case Report. *Cancer Treatment Reports* 1983; Vol 67 No 3, 287-291.
36. Amadori S, Papa G, Avvisati G, Petti M et al. Sequential combination of systemic high dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. *J Clin Oncology* 1984; 2: 98-101.
37. Herbst KD, Corder MP, Justice GR. Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system. *Cancer* 1976; 38: 1476-1478.
38. Duttera MH, Bleyer WA, Pomeroy TC et al. Irradiation, methotrexate toxicity and the treatment of meningeal leukemia. *Lancet* 1973; 2: 703-707.
39. Wallack EM, Reavis WM Jr, Hall CD. Primary brainstem reticulum cell sarcoma causing dementia. *Dis Nerv Syst* 1977; 38: 744-747.
40. Ruff RL, Petito CK, Rawlinson DG. Primary cerebral lymphoma mimicking multiple sclerosis. *Arch Neurol* 1979; 36: 598.
41. Williams RS, Crowell RM, Fisher CM et al. Clinical and radiological remission in reticulum cell sarcoma of the brain. *Arch Neurol* 1979; 36: 206-210.
42. Singh A, Strobos RJ, Singh BM et al. Steroid induced remissions in CNS lymphoma. *Neurology (NY)* 1982; 32: 1267-1271.
43. Scully RE, Mark EJ, McNeely BU. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1982. *New Eng J Med* 1982; 307: 359-368.
44. Vaquero J, Martinez R, Rossi E, Lopez R. Primary cerebral lymphoma: the "ghost tumor". Case report. *J Neurosurg* 1984; 60: 174-176.
45. Coca A, Goday A, Font J, Ingelmo M, Balcells A. Letter to the Editor re: Primary cerebral lymphoma: the "ghost tumor". *J Neurosurg* 1984; 61: 202.
46. Kinney T, Adams R. Reticulum cell sarcoma of brain. *Arch Neurol Psych* 1943; 50: 552-564.
47. Tanaka T, Nishimoto A, Doi A, Nagao S, Hujita M, Sesaki T, Yumoto T. Primary intracranial malignant lymphomas with particular reference to their pathogenesis. *Acta Path Jap* 1977; 27(6): 927-940.
48. Letendre L, Banks PM, Freese DF, Miller RH, Scanlon PW, Kiely JM. Primary lymphoma of the central nervous system. *Cancer* 1982; 49: 939-943.